

PRECEPTORSHIP PROGRAMME

Hereditary Cancer Genetics

Multidisciplinary management, standards
of care and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

27 MAY 2021

Co-Chairs

Judith Balmaña, Spain

Nicoline Hoogerbrugge, Netherlands

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME

HEREDITARY CANCER GENETICS

Multidisciplinary management, standards of care
and future perspectives

27 May 2021

CO-CHAIRS: Judith Balmaña, Spain
Nicoline Hoogerbrugge, Netherlands

SPEAKERS: Stefan Aretz, Germany
Gareth Evans, United Kingdom
Marjolijn Ligtenberg, Netherlands
Rolf Sijmons, Netherlands
Marc Tischkowitz, United Kingdom

LEARNING OBJECTIVES

- To learn about the best clinical practice in the multidisciplinary management of hereditary cancer syndromes
- To understand the molecular basis and heterogeneity of the genetic susceptibility to develop cancer
- To learn how to recognize, diagnose, treat and provide prevention recommendations to patients with a germline genetic susceptibility

ACCREDITATION

The programme of this event has been accredited with **5 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For the future details please refer to esmo.org

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered CEST (Central European Summer Time)

Thursday, 27 May 2021

10:00-10:10 10'	Welcome and introduction	Judith Balmaña, ES Nicoline Hoogerbrugge, NL
10:10-11:50 100'	SESSION 1 Challenges in hereditary cancer in 2021	Chair/Moderator: Judith Balmaña, ES
30'	Overview of the clinical challenges in hereditary cancer: from identification to treatment and prevention. The role of ERN-GENTURIS network in Europe	Nicoline Hoogerbrugge, NL
30'	Challenges of tumour sequencing, exome sequencing and liquid biopsies: incidental findings, interpretation of pathogenicity, ruling out a germline origin	Marjolijn Ligtenberg, NL
30'	Challenges of risk communication in hereditary cancer	Rolf Sijmons, NL
10'	Discussion	Faculty
11:50-12:05	Break	
12:05-13:00 55'	SESSION 2 Hereditary gastrointestinal cancer	Chair/Moderator: Judith Balmaña, ES
45'	What an oncologist needs to know about polyposis and GI hereditary syndromes	Stefan Aretz, DE
10'	Discussion	Faculty
13:00-15:00	Break	
15:00-15:55 55'	SESSION 3 Hereditary breast and ovarian cancer	Chair/Moderator: Nicoline Hoogerbrugge, NL
45'	What an oncologist needs to know about hereditary breast and ovarian cancer	Marc Tischkowitz, UK
10'	Discussion	Faculty
15:55-16:25 30'	SESSION 4 Atypical presentations of hereditary cancer	Chair/Moderator: Nicoline Hoogerbrugge, NL
20'	Are there cancer-related toxicities or benign manifestations that may sentinel a hereditary predisposition to cancer? (ie. radiation-induced tumours, chemosensitivity or hyper-toxicity, cutaneous manifestations)	Gareth Evans, UK
10'	Discussion	Faculty
16:25-16:40	Break	
16:40-17:20 40'	SESSION 5 Targeted therapies in BRCA-associated or MMR-deficient tumours	Chair/Moderator: Nicoline Hoogerbrugge, NL
30'	Germline mutations as a therapeutic target in cancer: PARPi and IO	Judith Balmaña, ES
10'	Discussion	Faculty

17:20-18:05 45'	SESSION 6 Participants clinical case discussion	Chairs/Moderators: Nicoline Hoogerbrugge, NL Judith Balmaña, ES
45'	Participants clinical case discussion (3x15')	Faculty
18:05-18:15 10'	Conclusion and farewell	Judith Balmaña, ES Nicoline Hoogerbrugge, NL

Note: Each 15 minutes slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion